Use of chemodenervation in dystonic conditions

Cleveland Clinic Journal of Medicine

Volumn 79, Issue SUPPL.2, 2012, Pages

  Hanson, Maurice ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

ARTICLE; CLASSIFICATION; DIAGNOSTIC ERROR; DRUG CONTRAINDICATION; DYSTONIA; DYSTONIC DISORDER; HUMAN; METHODOLOGY; NERVE BLOCK;

BOTULINUM TOXINS; DIAGNOSTIC ERRORS; DYSTONIA; DYSTONIC DISORDERS; HUMANS; NERVE BLOCK;

EID: 84868336013     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2a.05     Document Type: Article

References (22)

1. Dystonia fact sheet. National Institute of Neurological Disorders and Stroke Web Site. http://www.ninds.nih.gov/disorders/dystonias/detail_dystonias.htm. Updated October 27, 2011. Accessed April 17, 2012.
2. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3: 188-194.
3. Muller J, Kiechl S, Wenning GK, et al. The prevalence of primary dystonia in the general community. Neurology 2002; 59: 941-943.
4. Epidemiological Study of Dystonia in Europe Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol 2000; 24: 787-793.
5. Klein C, Kann M, Kis B, et al. Genetics of dystonia. Nervenarz 2000; 71: 431-441.
6. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, eds. Movement Disorders 2. London, UK: Butterworth; 1987: 332-358.
7. Doheny D, Danisi F, Smith C, et al. Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology 2002; 59: 1130-1131.
8. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord 1995; 10: 143-152.
9. Clinical use of botulinum toxin. NIH Consens Statement 1990; 8: 1-20.
10. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701-707.
11. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of Neuro-Bloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.
12. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446.
13. Dressler D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 2000; 7: 713-718.
14. Dystonia rating scales and scoring sheets. Movement Disorders Virtual University Web site. http://www.mdvu.org/library/ratingscales/dystonia/. Updated April 21, 2008. Accessed April 18, 2012.
15. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol 2001; 21: 85-90.
16. Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000; 22: 1516-1524.
17. Ceballos-Baumann AO. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001; 248(suppl 1): 14-20.
18. Giladi N, Meer J, Kidan H, Honigman S. Long-term remission of idiopathic cervical dystonia after treatment with botulinum toxin. Eur Neurol 2000; 44: 144-146.
19. Ben-Shlomo Y, Camfield L, Warner T, ESDE Collaborative Group. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 2002 ; 72: 608-614.
20. Fahn S, Hening WA, Bressman S, et al. Long-term usefulness of baclofen in the treatment of essential blepharospasm. Adv Ophthal Plastic Reconstr Surg 1985; 4: 219-226.
21. Callahan A. Blepharospasm with resection of part of orbicularis nerve supply. Arch Ophthalmol 1963; 70: 508-511.
22. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992; 42: 627-630.